SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

NATCO PHARMA

BSE: 524816 19 Aug 2025
Healthcare
₹ 892.2
Natco Pharma Ltd. specializes in Pharmaceuticals within the Healthcare sector.

NATCO PHARMA - Share Price & Details

Market Cap
₹15,973
High /Low
1,639 / 660.0
Stock P/E
9.42
Book Value
₹425.0
Dividend Yield
0.69
ROCE
32.8
ROE
₹28.0
Face Value
2.0
PEG Ratio
0.07
EVEBITDA
₹6.04
Debt
279
CMP / FCF
16.9
Debt to equity
₹0.04
NP Ann
1,883
High price all time
1,639
Piotroski score
₹8.0
Graham Number
952.0
No. Eq. Shares
17.9
Net CF
₹71.6
Net profit
1,695
Price to book value
2.09
Interest Coverage
₹95.0
Low price all time
7.6
Industry PE
33.8
Reserves
₹7,571
Free Cash Flow
₹1,300

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
NATCO PHARMA LTD.12523.04641.011927.025.9115,9739.42
Rainbow Children's Medicare Li3540.33517.23347.485.091595462.0
Blue Jet Healthcare Limited3630.12911.73547.585.261357037.8

Peer Comparison Chart


About NATCO PHARMA

Natco Pharma Ltd., with Security Code 524816, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Dividend Stocks: HAL, Godfrey Phillips, Coal India, among others to trade ex-dividend next week; Full list

(16 Aug 2025)
Dividend Stocks: Companies including Hindustan Aeronautics (HAL), Godfrey Phillips India, Coal India, Senco Gold, Rail Vikas Nigam Ltd,...
Read more →

Buy, Sell Or Hold: HAL, M&M, Oberoi Realty, Infosys, Natco Pharma, Coal India, NTPC — Ask Profit

(14 Aug 2025)
Should you hold shares of Mahindra & Mahindra Ltd? Should you add shares of Infosys Ltd at the current market price? Have you lost the...
Read more →

Natco Pharma stock downgraded to Sell by Axis Capital on revenue miss

(14 Aug 2025)
Investing.com - Natco Pharma Ltd (NTCPH:IN) was downgraded from Reduce to Sell by Axis Capital on Thursday, with its price target lowered to...
Read more →

Board of Natco Pharma recommends Interim Dividend

(13 Aug 2025)
Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 August 2025, has recommended a Interim Dividend...
Read more →

Natco Pharma Q1 results: Profit drops 22% YoY on pricing pressure; declares dividend

(12 Aug 2025)
Natco Pharma Ltd reported a 22.1% year-on-year (YoY) decline in consolidated net profit to ₹480 crore for Q1FY26, compared to ₹668.5 crore...
Read more →

NATCO Pharma Limited's (NSE:NATCOPHARM) market cap dropped ₹6.6b last week; Individual investors bore the brunt

(04 Aug 2025)
Key Insights Significant control over NATCO Pharma by individual investors implies that the general public has more...
Read more →

Company Updates